Quince Therapeutics (QNCX) AI Stock Analysis

• Market Cap: $164.26M
• Dividend Yield: N/A
• Average Volume (3M): 793.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.08
• Revenue Growth: N/A
• EPS Growth: 2.26%
• Country: US
• Employees: 36
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.25
• Shares Outstanding: 55,681,490
• 10 Day Avg. Volume: 745,683
• 30 Day Avg. Volume: 793,863
• PEG Ratio: -0.03
• Price to Book (P/B): 2.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.52
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -669.29
• Enterprise Value/Ebitda: -1.46
• 1Y Price Target: $7.00
• Price Target Upside: 132.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $3.50 ▲(16.28% Upside)

The score is held down primarily by very weak financial performance (no revenue, persistent losses, continued cash burn) and increased balance-sheet fragility from reduced equity and higher leverage. Technicals provide partial support with a generally positive longer-term trend and neutral RSI, but valuation is not supportive due to negative earnings, and the recent negative corporate update adds risk.

Positive Factors

Innovative Product Pipeline

The focus on innovative treatments and a strong pipeline targeting unmet medical needs positions Quince for potential breakthroughs, enhancing long-term growth prospects.

Strategic Partnerships

Strategic partnerships with larger firms provide financial support and market access, crucial for advancing drug candidates and achieving commercialization.

Manageable Debt Levels

Low debt levels provide financial flexibility and reduce risk, allowing the company to focus resources on R&D and strategic initiatives without significant debt burden.

Negative Factors

No Revenue Generation

The lack of revenue generation highlights challenges in achieving financial sustainability and necessitates successful product commercialization to ensure long-term viability.

Consistent Losses

Persistent losses indicate operational inefficiencies and the need for effective cost management to improve margins and achieve profitability over time.

Negative Cash Flow

Negative cash flow underscores difficulties in funding operations and growth initiatives, necessitating improved cash management strategies to sustain business activities.

Quince Therapeutics Business Overview & Revenue Model

Company Description

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

How the Company Makes Money

Quince Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products. Revenue is generated from sales of approved drugs, milestone payments, and royalties from partnerships or licensing agreements with larger pharmaceutical companies. In addition, the company may receive funding through research grants and collaborations with academic institutions or other biotech firms. Quince Therapeutics' earnings are significantly influenced by the successful progression of its drug candidates through clinical trials and obtaining necessary regulatory approvals.

Quince Therapeutics Financial Statement Overview

Summary

Quince Therapeutics faces significant financial challenges with no revenue generation, consistent losses, and substantial cash outflows. The company's balance sheet shows a manageable debt level but decreasing equity, raising concerns about long-term financial health. Without significant changes in revenue generation or cost management, the company may continue facing financial difficulties.

Income Statement

Quince Therapeutics reported no revenue over the past years, resulting in negative gross and net profit margins. The continuous negative EBIT and EBITDA margins highlight ongoing operational challenges in generating profitability. The lack of revenue growth further stresses the company's struggle to achieve financial stability.

Balance Sheet

The company's debt-to-equity ratio remains relatively low, reflecting modest leverage. However, the declining equity over time indicates potential financial instability. The equity ratio has been decreasing, showing a reduction in the company's financial buffer. Despite these challenges, the company maintains a significant cash balance relative to its debt.

Cash Flow

Quince Therapeutics has consistently negative free cash flow, indicating cash outflows exceed cash inflows. The operating cash flow to net income ratio is affected by the negative operating cash flow, suggesting difficulties in converting earnings into cash. The substantial negative free cash flow to net income ratio further emphasizes cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-119.00K	0.00	0.00	0.00	-344.00K	0.00
EBITDA	-54.74M	-35.98M	-26.82M	-50.99M	-89.97M	-78.56M
Net Income	-56.98M	-56.83M	-31.39M	-51.66M	-89.94M	-76.85M
Balance Sheet
Total Assets	109.90M	114.48M	180.20M	103.91M	133.23M	189.47M
Cash, Cash Equivalents and Short-Term Investments	26.29M	40.78M	75.06M	90.18M	106.80M	133.82M
Total Debt	17.99M	14.81M	13.81M	453.00K	1.16M	446.00K
Total Liabilities	108.84M	84.33M	95.12M	3.32M	14.64M	17.20M
Stockholders Equity	1.06M	30.15M	85.08M	100.59M	118.59M	172.26M
Cash Flow
Free Cash Flow	-38.98M	-32.16M	-18.45M	-44.17M	-63.11M	-50.87M
Operating Cash Flow	-38.50M	-31.90M	-18.29M	-44.04M	-62.93M	-50.82M
Investing Cash Flow	26.02M	21.91M	-5.76M	18.00M	58.95M	-52.43M
Financing Cash Flow	15.88M	-4.78M	143.00K	707.00K	6.81M	118.88M

Quince Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNCX, the sentiment is Positive. The current price of 3.01 is below the 20-day moving average (MA) of 3.28, above the 50-day MA of 2.88, and above the 200-day MA of 1.82, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 47.05 is Neutral, neither overbought nor oversold. The STOCH value of 36.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QNCX.

Quince Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADAG	52 Neutral	$74.94M	-2.64	-63.41%	―	-87.59%	11.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NKTX	48 Neutral	$154.84M	-1.48	-26.69%	―	―	25.84%
QNCX	47 Neutral	$164.26M	-2.47	-247.78%	―	―	2.26%
ANEB	44 Neutral	$46.43M	-4.72	-145.11%	―	―	23.10%
PLRX	42 Neutral	$81.73M	-0.45	-64.27%	―	―	14.19%
GBIO	39 Underperform	$37.93M	-0.60	-80.81%	―	-17.82%	57.32%

Quince Therapeutics Corporate Events

Quince Therapeutics Updates on NALL Study Efficacy

Quince Therapeutics, Inc. hosted a Virtual Investor Day on October 2, 2025, where they presented information regarding IntraBio Inc.’s Phase 2 study for N-acetyl-L-leucine (NALL) in patients with ataxia-telangiectasia. During the event, Quince made a statement about the study’s unknown efficacy and failure across all endpoints, which was later removed from their presentation and video. This statement was based on an article from the European Journal of Paediatric Neurology, which indicated that while some symptoms improved, NALL did not significantly benefit motor function or ataxia symptoms. Quince advises investors not to rely on their initial statement.

The most recent analyst rating on (QNCX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.